RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers

RenovoRx, Inc.

2025-Q3 EPS reported -$0.24 revenue$885,000

Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.
Net loss $2.9M for Q3 vs $2.5M in Q3 2024; cash $10M as of Sept 30, 2025.
Phase III TIGeR-PaC trial enrollment expected to complete early 2026 with final data in 2027.
Expanded from 5 to 14 approved cancer center customers for RenovoCath since start of 2025.
Hired Philip Stocton as Senior Director of Sales and added two regional sales managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.